Why should a Fishman regimen not be used for the treatment of bronchiectasis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Why the Fishman Regimen Should Not Be Used for Bronchiectasis

The Fishman regimen is not recommended for bronchiectasis because it involves routine use of inhaled corticosteroids (ICS), which current guidelines explicitly advise against in non-cystic fibrosis bronchiectasis due to lack of efficacy and increased infection risk.

The Core Problem with ICS in Bronchiectasis

Bronchiectasis is fundamentally a disease of neutrophilic inflammation, not eosinophilic inflammation 1. This is the critical distinction that makes the Fishman approach inappropriate:

  • ICS target eosinophilic inflammation (effective in asthma/COPD) but have minimal impact on neutrophilic inflammation
  • Bronchiectasis involves chronic bacterial colonization where immunosuppression from ICS can worsen outcomes
  • The immunosuppressive properties of ICS can increase bacterial infection burden in airways already prone to chronic infection 1

What the Guidelines Actually Say

Both major 2025-2026 guidelines take a clear stance:

The European Respiratory Society (2025) issues a conditional recommendation suggesting NOT to routinely use inhaled corticosteroids in bronchiectasis 2. The American College of Chest Physicians (2026) guideline similarly does not recommend routine ICS use 3.

The evidence shows that over 50% of bronchiectasis patients are prescribed ICS without scientific justification, contrary to guideline recommendations 1. This represents widespread inappropriate prescribing.

When ICS Might Be Appropriate (The Only Exception)

ICS should only be used in bronchiectasis patients who have documented comorbid asthma or COPD 4, 5. In these specific cases:

  • The ICS is treating the asthma/COPD component, not the bronchiectasis
  • Careful monitoring for increased infections is mandatory
  • Consider gradual dose reduction if asthma is well-controlled and bronchiectasis remains stable 5

What Should Be Used Instead

The evidence-based approach for bronchiectasis focuses on:

  1. Airway clearance techniques (strong recommendation) 2
  2. Long-term macrolides for patients at high risk of exacerbations (strong recommendation) 2
  3. Long-term inhaled antibiotics for chronic Pseudomonas aeruginosa infection in high-risk patients (strong recommendation) 2
  4. Pulmonary rehabilitation for impaired exercise capacity (strong recommendation) 2
  5. Mucoactive therapy (nebulized saline) to loosen secretions 4

Common Pitfall to Avoid

The most common error is reflexively prescribing ICS because the patient has "airways disease" and chronic cough. Bronchiectasis requires a fundamentally different treatment paradigm than asthma or COPD. The pathophysiology is infection and neutrophilic inflammation, not reversible airway obstruction or eosinophilic inflammation.

If a patient is already on ICS without documented asthma/COPD, consider tapering and discontinuing while monitoring for any change in symptoms 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.